SCHEMBL29619093

SCHEMBL29619093

Cc1noc(C)c1-c1cc(NC(=O)c2ncnn2C)ccc1OC[C@H]1CCCCN1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.36
CHRNA4 P43681 1/20 0.36
CREBBP Q92793 1/20 0.35
CHRNB4 P30926 2/20 0.35
CHRNA3 P32297 2/20 0.35
CHRNA5 P30532 1/20 0.35
BRD4 O60885 1/20 0.35
BRD2 P25440 1/20 0.35
BRD3 Q15059 1/20 0.35
HTR2A P28223 5/20 0.34
MAPT P10636 1/20 0.34
HTR2C P28335 4/20 0.34
HDAC1 Q13547 1/20 0.34
IRAK4 Q9NWZ3 1/20 0.34
HSP90AA1 P07900 1/20 0.33
HSP90AB1 P08238 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29619087 0.87 NPC1 (0.43) CHRNB2CHRNA4CREBBPCHRNB4CHRNA3
SCHEMBL29619129 0.87 BRD4 (0.36) CHRNB2CHRNA4CREBBPCHRNB4CHRNA3
SCHEMBL29619135 0.86 NAMPT (0.39) CHRNB2CHRNA4CREBBPCHRNB4CHRNA3
SCHEMBL29619090 0.86 HTR2A (0.36) CHRNB2CHRNA4CREBBPHTR2AHTR2C
SCHEMBL29619132 0.85 TAS2R8 (0.43) CHRNB2CHRNA4CREBBPCHRNB4CHRNA3
SCHEMBL31199048 0.85 LMNA (0.41) CHRNB2CHRNA4CREBBPHTR2AMAPT
SCHEMBL29619137 0.84 CREBBP (0.39) CHRNB2CHRNA4CREBBPCHRNB4CHRNA3
SCHEMBL29619050 0.84 CHRNB2 (0.40) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA5
SCHEMBL29619060 0.84 CHRNB2 (0.40) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA5
SCHEMBL29619068 0.83 MET (0.42) CREBBPHTR2AMAPTHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376090-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2024-11-14 US disclosed
EP-4236942-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2023-09-06 EP disclosed
WO-2022093850-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2022-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376090-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO HTR2A, HTR5A, HTR1A CHRNB2 144/4885CHRNA4 105/4885CREBBP 2282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.